Global Alzheimer’s Disease Diagnostic Market

Alzheimer’s Disease Diagnostic Market size was valued at US$ 3.91 Bn in 2024 and the total revenue is expected to grow at 12.8% through 2025 to 2032, reaching nearly US$ 10.25 Bn in the forecast period.

Alzheimer’s Disease Diagnostic Market Overview:

Alzheimer’s disease is the most common type of dementia and a kind of progressive disease beginning with mild memory loss to leading towards loss of the ability to respond to any conversation and environment. Alzheimer’s diseases involve parts of the brain that controls thought, and language. Moreover, this disease has no care to date but several medicines support the medical condition and temporarily reduce the symptoms.To know about the Research Methodology :- Request Free Sample Report

Alzheimer’s Disease Diagnostic Market Dynamics:

The factors driving the growth of the Global Alzheimer’s Disease Diagnostic market are growing chronic diseases like dementia, investment in biomarkers for drug development, increasing pipeline drug development, and increasing treatment options and sophisticated diagnostic treatment for early detection of chronic disease. According to the World Alzheimer report, in 2022, about 50 million people worldwide are reported with Alzheimer's disease and dementia. And this no. is further estimated to reach 152 million by 2050.

The major restraining factor hampering the growth of the market is time-consuming clinical trials and the approvals by the medical authorities. Moreover, huge investments and the risk of failure can hamper the market growth.

The government initiatives and medical & academic institutes are investing a huge amount in research and development to investigate the underline treatment for the disease. An increase in no. of clinical studies and pathological studies with research & development is anticipated to increase the Alzheimer’s diseases diagnostic market in the forecast period.

In addition, the launching of new diagnostic techniques and approvals from government authorities is likely to motivate market growth in the forecast period. For instance, in 2020, C2N Diagnostic manufactured and launched the -Percivity AD Blood Test Europe and further got approvals from the European government. This process is built on mass spectrometry and is used for the diagnosis of Alzheimer's disease and the relating pathology lab.

Further, in 2021, Biogen & Eisai Co. got the approval of a biology license application by the US Food and Drug Administration (FDA) for a cure named -Aducanumab. As it is under observation for the treatment and cure of Alzheimer’s disease.

Alzheimer’s Disease Diagnostic Market Segment Analysis:

Cholinesterase Inhibitors is dominating the Therapeutics segment of the Global Alzheimer’s Disease Diagnostic Market:

Cholinesterase inhibitor is estimated to gain the largest market share in the forecast period. The key factors attributing to the growth of the market are prominent pharmacological actions like delaying loss of mental ability in dementia and people suffering from Alzheimer’s disease. Moreover, Cholinesterase level can be used as an indirect marker of arsenic exposure. Cholinesterase inhibitors are prescribed to treat symptoms related to memory, thinking, language, judgment, and other stimulating process or responses. Moreover, there are numerous drugs used for the treatment of Alzheimer’s Diseases approved by the US FDA in the treatment of dementia are Exelon and Aricept, and Razadyne used to treat mild to moderate Alzheimer’s disease.

In addition, companies are investing a huge amount in the research and development sector for new drug formation. For instance, in January 2021, Corium International Inc. marched a new drug Application and ADLARITY (donepezil transdermal system) in the treatment of Alzheimer’s disease.

The CFS Test for Alzheimer’s Diseases segment is considered to supplement the growth of the Global Alzheimer’s Disease Diagnostic Market.

CFS Test for Alzheimer’s Diseases is dominating the diagnosis segment of the Global Alzheimer’s Disease Diagnostic Market. The key factors attributing to the growth of the market are the increasing use of Cerebrospinal Fluid (CSF) in the diagnosis of Alzheimer’s disease. The sample CSF is collected from the patient's back by injection.

Moreover, a CSF test is performed to evaluate the concentration of various substrates and cells in CSF to identify the condition of the patient and affecting the brain and spinal cord. Cerebrospinal fluid CSF amyloid-beta (Aβ)1–42, total tau (T-tau), and phosphorylated tau (P-tau) have utility in differentiating Alzheimer’s Disease (AD) from controls and in predicting conversion from mild intellectual diminishing (MCI) to Alzheimer’s Disease (AD) dementia.

Braine Imaging has played a vital role in the study and diagnosis of Alzheimer’s Disease (AD) and is gaining wider acceptance in the market due to digital scanning. The techniques used in brain imaging are computed tomography (CT) and magnetic resonance imaging (MRI), these techniques are used diagnostically to rule out the cause of dementia.

Alzheimer’s Disease Diagnostic Market Regional Insights:

Global Alzheimer’s Disease Diagnostic Market Regional Insights is segmented into North America, Asia Pacific, Europe, Latin America, Middle East, and Africa.

North America is dominating the Global Alzheimer’s Disease Diagnostic Market Regional Insights with the largest market share of 39.5% in the forecast period. The growth is dominated by the increasing geriatric population and rising COVID-19 infection. As the older population is more prone to chronic diseases and dementia. As per Alzheimer’s Association in 2022, more than 5.82 billion Americans are suffered from Alzheimer’s, and as per US Census Bureau data, in 2021, about 54 million Americans were suffered and the age of the patient was above 65.

The state leading in North America is the US with the highest no. of Alzheimer’s Disease (AD) involvement together with management. Also, the total healthcare expenditure for a patient suffering from AD was around USD 357,296 in 2019. Owing to this factor, North America is leading in the Alzheimer’s Disease Diagnosis market.

Moreover, amplified studies on Alzheimer’s Disease are likely to fuel the growth of the market in the forecast period. As per National Clinical Trials Registry (NTC) in the US around 144 active clinical trials are under process in Alzheimer’s Disease diagnosis. Hence, this factor is estimated to boost the growth of the market in the forecast period.

The objective of the report is to present a comprehensive analysis of the Global Alzheimer’s Disease Diagnostic Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the Global Alzheimer’s Disease Diagnostic Market dynamics, structure by analyzing the market segments and project the Global Alzheimer’s Disease Diagnostic Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Global Alzheimer’s Disease Diagnostic Market make the report investor’s guide.

Global Alzheimer’s Disease Diagnostic Market Scope: Inquire before buying

Alzheimer’s Disease Diagnostic Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Alzheimer’s Disease Diagnostic Market Key Players are:

1. Eli Lilly and Company
2. TauRx (Republic of Singapore)
3. Alector LLC
4. Accera, Inc.
5. Treventis Corporation
6. Neuro-Bio Ltd
7. Cognition Therapeutics Inc
8. Hoffmann-La Roche
9. Novartis AG
10. Merck & Co.
11. Pfizer Inc.
12. Allergan PLC
13. Daiichi Sankyo Co.

FAQs:

1. What is the global Alzheimer’s Disease Diagnostic market share in 2024?

Ans: Global Alzheimer’s Disease Diagnostic market share in 2024 was estimated as 3.91 Billion USD.

2. What is the global Alzheimer’s Disease Diagnostic market growth?

Ans: The global Alzheimer’s Disease Diagnostic market is anticipated to grow with a CAGR of 12.8 % in the forecast period and is likely to reach USD 10.25 Billion by the end of 2032.

3. Which Therapeutics segment is expected to dominate the global Alzheimer’s Disease Diagnostic market during the forecast period?

Ans: The Cholinesterase Inhibitors segment is considered to dominate the market due to the largest market size and the safety, efficacy related to Cholinesterase Inhibitors as this drug has shown promising results in lowering the symptoms of AD.

4. Which region is expected to dominate the global Alzheimer’s Disease Diagnostic during the forecast period?

Ans: North America dominates the Alzheimer’s Disease Diagnostic market owing to the dominance of biologics and pharmaceutical drug market, rising population, and occurrence of Alzheimer’s Disease in the geriatric population.

5. What is the key driving factor for the growth of the global Alzheimer’s Disease Diagnostic market?

Ans: The demand for increasing diagnostic treatment and medical facilities together with the increasing geriatric population are the key factors driving the global Alzheimer’s Disease Diagnostic market.